Synthetic method and application of facial bionic ceramide

Abstract

The invention discloses a facial bionic ceramide, which is a facial bionic fatty acid phytosphingosine ceramide or / and a facial bionic fatty acid sphingosine ceramide obtained by carrying out amidation reaction on facial bionic vegetable fat from a plant source and a long-chain sphingosine compound, the facial bionic vegetable fat is prepared from the following components in percentage by mass: 25%-60% of eicosamonoenoic acid, 15%-40% of docosamonoenoic acid, 5%-20% of oleic acid, 2%-10% of linoleic acid, 0.5%-5% of palmitic acid, 0.1%-2% of stearic acid, 0.5%-5% of docosadienoic acid and 0.1%-5% of nervonic acid. The long-chain sphingosine compound is phytosphingosine or / and sphingosine. The C16-C24 composite ceramide NP is synthesized through the continuous flow reaction of the continuous flow microchannel reactor, so that the maximum effect of ceramides with different lengths and saturations is achieved.

Description

Technical Field

[0001] The invention belongs to the technical field of ceramide synthesis, and particularly relates to a synthesis method and application of facial bionic ceramide. Background Art

[0002] Ceramide is a type of phospholipid with ceramide as the skeleton that exists in the skin. It is a sphingolipid composed of sphingosine long-chain bases and fatty acids, mainly ceramide phosphorylcholine and ceramide phosphorylethanolamine. Ceramide is a common structural unit of (neuro)sphingolipids and an intermediate metabolite of sphingolipids. It has a similar structure to the material that constitutes the stratum corneum of the skin. It can quickly penetrate into the skin and combine with the water in the stratum corneum to form a network structure that locks in moisture. It plays an important role in the formation of the epidermal stratum corneum. Recent studies have shown that when the skin becomes dry, flaky, and cracked, and its barrier function is significantly reduced, supplementing the skin with ceramide can quickly restore moisturizing and barrier functions.

[0003] At present, 21 types of ceramides have been discovered in the human stratum corneum. Studies have found that the fatty acids bound to sphingoid bases show diverse characteristics, most of which are unbranched hydrocarbon chains with lengths between C16, C18, C22, C24, and C26. The ceramide with the highest content in the skin is NP (29.4%), and the fatty acid chain of ceramide NP is mainly a long saturated hydrocarbon chain, the most common of which is between C18, C24, C26, and C28. The distribution of ceramide types in different parts of the human body is also different, and ceramide NP accounts for about 12% of facial ceramides. Therefore, considering the distribution of facial ceramides, by simulating the proportion of facial ceramide NP, the type of ceramide NP required for the face can be better supplemented, thereby repairing the skin barrier, anti-inflammatory and anti-aging effects.

[0004] Ceramides derived from plant oils and fats can form an effective skin barrier to prevent moisture loss and resist external damage due to their green and natural raw material sources and properties similar to those of skin ceramide components.

[0005] Existing ceramide products do not take into account the various types of ceramide NPs in human skin and the biomimetic properties of various C chain lengths. Existing ceramide products rarely contain ceramides with long C chains such as C20, C22, and C24.

[0006] For example, patent document CN117535358A discloses a method for synthesizing ceramide III compounds, which includes the following steps: in phytosphingosine and fatty acid esters, using immobilized lipase as a biocatalyst and cyclopentyl methyl ether as a reaction medium, a constant temperature catalytic reaction is carried out to make phytosphingosine and fatty acid ester acyl donors undergo amidation reaction to synthesize ceramide III compounds. However, the document only studies the activity of C18 fatty acid esters, and does not conduct application research on fatty acid esters of other carbon chain lengths. At the same time, a large amount of chemical solvent cyclopentyl methyl ether is used in the document, which has a certain risk of environmental pollution.

[0007] Patent document CN117304063A discloses that argan oil fatty acid and sphingosine compounds are reacted under the conditions of a condensing agent and an organic base to obtain argan oil ceramide; wherein the composition of the argan oil fatty acid is: 35-50wt% oleic acid, 30-50wt% linoleic acid, 5-15wt% palmitic acid, 2-8wt% stearic acid, 0.1-1wt% arachidic acid, 0.01-0.5wt% linolenic acid, 0-0.5wt% behenic acid, and 0-0.5wt% arachidonic acid; and the sphingosine compound is selected from sphingosine, phytosphingosine, and dihydrosphingosine. However, this document uses environmentally unfriendly chemical solvents in the hydrolysis of oils and the docking reaction of ceramides, and also uses condensation agents with allergenic risks. The separation and purification of the products are relatively troublesome, and the residual chemical solvents, condensation agents and organic bases may affect the safety of the products. In addition, the carbon chains of fatty acids in plant oils are mainly concentrated between C16 and C18, which is quite different from the distribution of ceramides in the human face, and cannot play a good facial bionic effect.

[0008] Moreover, the ceramide in the prior art does not adopt a more efficient continuous flow reaction to synthesize ceramide. Summary of the invention

[0009] The purpose of the present invention is to provide a method for synthesizing facial bionic ceramide and its use, so as to overcome the problems of using a large amount of chemical solvents and sensitizing condensing agents in the prior art, and at the same time overcome the defect that the ceramide NP prepared by the prior art is greatly different from the ceramide NP of the human face and cannot achieve good bionic effect.

[0010] The purpose of the present invention is achieved through the following technical solutions: The facial bionic ceramide of the present invention is prepared by amidation reaction of facial bionic plant oil from plant sources with long-chain sphingosine compounds to obtain facial bionic fatty acid phytosphingosine ceramide or / and facial bionic fatty acid sphingosine ceramide; characterized in that: The facial bionic plant oil is composed of the following components by mass fraction: 25% to 60% eicosapentaenoic acid, 15% to 40% docosenoic acid, 5% to 20% oleic acid, 2% to 10% linoleic acid, 0.5% to 5% palmitic acid, 0.1% to 2% stearic acid, 0.5% to 5% docosadienoic acid, and 0.1% to 5% neuraminic acid; these are necessary components, and the content of fatty acid components in each batch will vary due to factors such as plant variety, origin, climate, and picking season; The long-chain sphingosine compound is phytosphingosine or / and sphingosine; wherein the phytosphingosine is 2-amino-octadecane-1,3,4-triol (CAS No.: 13552-11-9), and the sphingosine is 2-amino-4-octadecene-1,3-diol (CAS No.: 89678-50-2).

[0011] Furthermore, the facial bionic oil fatty acid also contains 0-0.5% linolenic acid.

[0012] The facial biomimetic fatty acid phytosphingosine ceramides include: eicosapentaenoic acid phytosphingosine ceramide, docosenoic acid phytosphingosine ceramide, oleic acid phytosphingosine ceramide, linoleic acid phytosphingosine ceramide, palmitic acid phytosphingosine ceramide, stearic acid phytosphingosine ceramide, docosadienoic acid phytosphingosine ceramide, nervonic acid phytosphingosine ceramide; linolenic acid phytosphingosine ceramide is not necessarily contained and is an optional component; The facial biomimetic fatty acid sphingosine ceramides include: eicosapentaenoic acid sphingosine ceramide, docosenoic acid sphingosine ceramide, oleic acid sphingosine ceramide, linoleic acid sphingosine ceramide, palmitic acid sphingosine ceramide, stearic acid sphingosine ceramide, docosadienoic acid sphingosine ceramide, and neratinic acid sphingosine ceramide; linolenic acid sphingosine ceramide is not necessarily contained and is an optional component.

[0013] Furthermore, the facial biomimetic fatty acid phytosphingosine ceramide and / or the facial biomimetic fatty acid sphingosine ceramide described in the present invention include the compound itself, its isomers, its hydrates and / or its solvates.

[0014] The second object of the present invention is to provide a method for synthesizing the facial bionic ceramide, comprising the following steps: (1) preheating facial bionic plant oil to 40-65°C as material A; dissolving a long-chain sphingosine compound in anhydrous ethanol and heating it to 40-65°C as material B; (2) mixing the material A and the material B through a micro mixer, and then feeding them into a microchannel reactor to perform a continuous flow reaction at a temperature of 70-90°C, collecting the effluent, and obtaining the facial bionic ceramide through post-treatment.

[0015] Preferably, the continuous flow microchannel reactor of the present invention uses a micro-reaction device with a pipeline inner diameter of 0.1 to 2.5 mm (preferably a pipeline inner diameter of 0.8 to 2.0 mm) and a pipeline volume of 50 to 100 mL; it has the following advantages: (1) The microchannel reactor has a very large specific surface area, which can increase the mass transfer and heat transfer efficiency by orders of magnitude and reduce the high-temperature reaction time, thereby avoiding the destruction of trace active ingredients in oils and fats; (2) The amount of the reaction material can be accurately controlled by an injection pump to avoid the increase of side reactions caused by inaccurate local chemical measurement, resulting in a more complex product system; (3) The microchannel reactor equipment occupies a small area, is easy to operate, and has a low production cost.

[0016] The post-treatment is as follows: cooling the effluent to room temperature, adding an appropriate amount of water, and cooling to 0-6°C to precipitate solids, filtering to obtain a filter cake; rinsing with anhydrous ethanol to obtain a wet product, and then drying under reduced pressure to obtain the facial bionic ceramide.

[0017] The third object of the present invention is to provide the use of the facial bionic ceramide in cosmetics, dietary products or health products; for example: the facial bionic ceramide (FSIC for short) of the present invention has the effect of enhancing the activity of human keratinocytes and accelerating the healing of skin tissue. Compared with the blank control group, the cell activity is above 101.04% at a concentration of 500 mg / L; it has anti-inflammatory effects. At a concentration of 62.5 mg / L, the interleukin 6 (IL-6) factor level is 0.64 times that of the lipopolysaccharide-induced cellular inflammation model (LPS).

[0018] Compared with the prior art, the present invention has the following advantages: 1. Based on the idea of ​​facial bionics, the present invention synthesizes C16-C24 composite ceramide NP, whose composition is similar to that of ceramide NP contained in facial skin, so as to maximize the efficacy of ceramides of different lengths and saturations, among which ceramide NPs with lengths of C20 and C22 have the highest content, and also contain ultra-long chain C24 ceramide NP.

[0019] Compared with medium-chain ceramide NPs, long-chain and ultra-long-chain ceramide NPs have better barrier repair function. It was found that the number of medium-chain ceramide NPs increased, while the number of long-chain and ultra-long-chain ceramide NPs decreased in the skin of patients with atopic eczema; this makes the facial bionic ceramide FSIC of the present invention show excellent efficacy in enhancing the vitality of human keratinocytes, accelerating skin tissue healing, and anti-inflammation.

[0020] 2. The present invention uses plant-derived facial bionic plant oils and long-chain sphingoid bases as starting materials, and synthesizes ceramide products through a continuous flow reaction of a continuous flow microchannel reactor. The oil heating reaction time is short and will not destroy its activity, especially some trace nutrients contained in the oil. Only ethanol is used as a solvent during the reaction process, which meets the requirements of green technology. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is the HPLC spectrum of Example 1.

[0022] Figure 2 This is the LC-MS spectrum of Example 2.

[0023] Figure 3-4 The bar graph is a cell proliferation activity test result of test examples 1 and 2.

[0024] Figure 5-6 The results of the cell migration test in Experimental Examples 1 and 2 are shown.

[0025] Figure 7 To test the anti-inflammatory and repairing efficacy of Experimental Example 3, a bar graph of IL-6 factor expression was detected.

[0026] Figure 8 It is a schematic diagram of the process flow of the present invention. DETAILED DESCRIPTION

[0027] The present invention is further described below by means of specific embodiments, which are only used to illustrate the present invention rather than to limit the present invention.

[0028] Example 1

[0029] A method for synthesizing facial bionic ceramide comprises the following steps: (1) Preheat 80 g of facial bionic plant oil to 60 °C as material A; dissolve 50 g of phytosphingosine in 120 mL of anhydrous ethanol and heat to 60 °C as material B; (2) If Figure 8 As shown, the material A and the material B are pumped into a micro mixer for mixing, and then sent into a microchannel reactor for continuous flow reaction. The inner diameter of the pipeline of the microchannel reactor is selected to be 2.0 mm, the pipeline length is 16 m, and the pipeline volume is 50 mL; the reaction temperature is 80° C.; and the effluent is collected; (3) The effluent was cooled to room temperature, 100 mL of water was added, some solids were precipitated, and then further cooled to 4°C to precipitate a large amount of solids. The filter cake was obtained by filtration. The filter cake was then rinsed with anhydrous ethanol (30 mL each time) for 3 times to obtain a wet product, which was then dried under reduced pressure to obtain 80 g of facial bionic phytosphingosine ceramide, with a yield of 60%.

[0030] The facial biomimetic phytosphingosine ceramide was analyzed by HPLC. The HPLC chromatographic conditions were: using Shimadzu high performance liquid chromatograph (LC-2030C 3D Plus), using Innova! ODS-2 4.6×250mm×150mm chromatographic column, column temperature: 30°C, injection volume: 20μL, flow rate: 1.0mL / min, evaporation temperature: 40°C, carrier gas flow rate: 2.5L / min, mobile phase: 5% water + 95% methanol.

[0031] The HPLC profile of the product is shown in Figure 1 The retention time of each component is as follows: linoleic acid phytosphingosine ceramide 12.59min, palmitic acid phytosphingosine ceramide 14.67min, oleic acid phytosphingosine ceramide 15.94min, stearic acid phytosphingosine ceramide 21.40min, arachidonoyl phytosphingosine ceramide 22.77min (classified as eicosanonoyl ceramide), 5-eicosanonoyl phytosphingosine ceramide 25.57min (classified as eicosanonoyl ceramide), 5,13-docosadienoyl phytosphingosine ceramide 27.20min, erucic acid phytosphingosine ceramide 33.32min (classified as eicosanonoyl ceramide), 5-docosanonoyl-phytosphingosine ceramide 38.27min (classified as eicosanonoyl ceramide), and nervonic acid phytosphingosine ceramide 49.57min.

[0032] from Figure 1 The determination results showed that the content of phytosphingosine ceramide with eicosapentaenoic acid was 42.86%, the content of phytosphingosine ceramide with docosenoic acid was 30.32%, the content of phytosphingosine ceramide with oleic acid was 10.55%, the content of phytosphingosine ceramide with linoleic acid was 8.51%, the content of phytosphingosine ceramide with palmitic acid was 2.12%, the content of phytosphingosine ceramide with stearic acid was 0.84%, the content of phytosphingosine ceramide with docosadienoic acid was 2.27%, the content of phytosphingosine ceramide with nervonic acid was 1.02%, and the content of phytosphingosine ceramide with linolenic acid was 0.07%.

[0033] Example 2

[0034] A method for synthesizing facial bionic ceramide comprises the following steps: (1) Preheat 80 g of facial bionic plant oil to 60 °C as material A; dissolve 50 g of sphingosine in 120 mL of anhydrous ethanol and heat to 60 °C as material B; (2) If Figure 8As shown, the material A and the material B are pumped into a micro mixer for mixing, and then sent into a microchannel reactor for continuous flow reaction. The inner diameter of the pipeline of the microchannel reactor is selected to be 1.2 mm, the pipeline length is 88.5 m, and the pipeline volume is 100 mL; the reaction temperature is 80° C.; and the effluent is collected; (3) The effluent was cooled to room temperature, 120 mL of water was added, some solids were precipitated, and then further cooled to 4°C to precipitate a large amount of solids. The filter cake was filtered and then rinsed with anhydrous ethanol (30 mL each time) for 3 times to obtain a wet product, which was then dried under reduced pressure to obtain 75 g of facial biomimetic sphingosine ceramide, with a yield of 58%.

[0035] The facial biomimetic sphingosine ceramide was analyzed by LC-MS. The LC test conditions were as follows: chromatographic column: Acclaim RSLC120-C18, 2.1*100mm 2.2µm; mobile phase: A-5% water (containing 0.1% formic acid) B-95% methanol (containing 0.1% formic acid), isocratic elution, flow rate: 0.5mL / min, detection wavelength: 204nm, sample concentration: 8-10mg / mL, injection volume: 5µL; MS test conditions: vaporizer temperature: 282℃, ion transfer tube temperature: 300℃, Source voltage I: 3027V, sheath gas pressure: 49.9psig, auxiliary gas pressure: 5.7psig, sweep gas pressure: 0.5psig, mass range: 100-1000.

[0036] The LC spectrum of the obtained product, facial biomimetic sphingosine ceramide, is shown in Figure 2 The molecular weights of the products are: containing linoleic acid sphingosine ceramide C 36 H 68 NO3 + [M+H] + 562.48, palmitic acid sphingosine ceramide C 34 H 67 NO3Na + [M+Na] + 560.46, oleic acid sphingosine ceramide C 36 H 69 NO3Na + [M+Na] + 586.48, stearic acid sphingosine ceramide C 36 H 71 NO3Na + [M+Na] + 588.61, eicosapentaenoic acid ceramide C 38 H 74 NO3 + [M+H] + 592.50, docosahexaenoic acid-sphingosine ceramide C40 H 77 NO3Na + [M+Na] + 642.58, docosahexaenoic acid sphingosine ceramide C 40 H 75 NO3Na + [M+Na] + 640.56, ceramide C 42 H 81 NO3Na + [M+Na] + is 670.52. Figure 2 It can be obtained that the content of eicosenoic acid sphingosine ceramide in the product is 38.86%, the content of docosenoic acid sphingosine ceramide is 33.12%, the content of oleic acid sphingosine ceramide is 9.46%, the content of linoleic acid sphingosine ceramide is 9.21%, the content of palmitic acid sphingosine ceramide is 2.08%, the content of stearic acid sphingosine ceramide is 0.92%, the content of docosadienoic acid sphingosine ceramide is 2.68%, the content of neronic acid sphingosine ceramide is 0.92%, and the content of linolenic acid sphingosine ceramide is 0.04%.

[0037] Test Example 1 The keratinocyte viability and proliferation test (MTT method) was used to detect the cell proliferation activity of the product of Example 1-2: HaCaT cells were cultured at 1×10 4 The cells were seeded at a density of 100 μL / well in a 96-well plate and incubated overnight in an incubator. After 24 hours, the supernatant was discarded, 100 μL of culture medium containing samples (products of Example 1) of different concentrations was added, and the culture medium was removed after further incubation for 24 hours. 100 μL of MTT was added to each well, and the absorbance at 450 nm was measured to calculate the cell survival rate = A 给药孔 / A 空白孔 ×100%. The result is Figure 3 (Example 1) and Figure 4 (Example 2) shown.

[0038] The high concentration of facial bionic ceramide in Example 1 of the present invention has a promoting effect on cell viability. The cell survival rates at concentrations of 1.95, 7.81, 31.25, 125, 250, and 500 mg / L are 89.56%, 86.69%, 93.26%, 96.85%, 98.41%, and 101.04%, respectively, showing cell proliferation efficacy at high concentrations.

[0039] The high concentration of facial bionic ceramide in Example 2 of the present invention has a promoting effect on cell viability. The cell survival rates at concentrations of 1.95, 7.81, 31.25, 125, 250, and 500 mg / L are 107.18%, 108.14%, 101.12%, 104.97%, 106.63%, and 108.29%, respectively, showing cell proliferation efficacy at high concentrations.

[0040] Test Example 2 Cell migration was used to evaluate skin barrier repair.

[0041] Principle: When cells grow to a fused monolayer state, a scratch tool is used to create a blank area on the fused monolayer of cells. The cells in the blank area are removed by mechanical force. After a period of culture, the migration of cells to the cell-free area is observed, and the migration distance of cells is measured to reflect the migration ability of cells.

[0042] The scratch test results are as follows Figure 5 (Example 1) and Figure 6 As shown in (Example 2), the scratch width of the experimental group (the products of Example 1 and Example 2) is narrower than that of the solvent control group, indicating that facial bionic ceramide (FSIC) has better tissue healing ability. The compound of the present invention significantly improves the cell healing rate and has good skin tissue repair activity.

[0043] Test Example 3 The LPS-induced cell method was used to detect the anti-inflammatory and repairing effects of the product of Example 2: macrophages were cultured at a density of 1×10 4 The cells were seeded in 96-well plates and placed in an incubator overnight. After 24 hours, the supernatant was discarded and 100 μL of samples of different concentrations diluted with DMEM medium were added. The negative control group was DMEM medium without samples. Each group had 3 replicates and was incubated in an environment of 5wt% CO2 and 37°C. 2 hours after administration, 10 μg / mL LPS was added to the lipopolysaccharide model group and the experimental group and incubated together for 24 hours. After the reaction, 50 μL of the cell supernatant was taken and the intracellular IL-6 gene expression was detected using an IL-6 ELISA kit.

[0044] The results are as follows Figure 7As shown in the figure, under the stimulation of LPS at a working concentration of 10 μg / mL, the IL-6 level was 3.49 times the basal level. Under the action of facial bionic ceramide (FSIC) at concentrations of 7.81, 15.63, 31.25, and 62.5 mg / L, the IL-6 factor level was significantly reduced, which was 0.91, 0.77, 0.69, and 0.64 times that of the LPS model group, respectively, in a dose-dependent manner, which proves that the facial bionic ceramide (FSIC) of Example 2 has a good anti-inflammatory effect and can promote the repair of inflammatory damaged skin.

[0045] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A facial bionic ceramide, which is prepared by amidation reaction of facial bionic plant oil from plant sources with long-chain sphingosine compounds to obtain facial bionic fatty acid phytosphingosine ceramide or / and facial bionic fatty acid sphingosine ceramide; characterized in that: The facial bionic plant oil is composed of the following components in mass fractions: 25% to 60% eicosapentaenoic acid, 15% to 40% docosenoic acid, 5% to 20% oleic acid, 2% to 10% linoleic acid, 0.5% to 5% palmitic acid, 0.1% to 2% stearic acid, 0.5% to 5% docosadienoic acid, and 0.1% to 5% neuraminic acid; the long-chain sphingosine compound is phytosphingosine or / and sphingosine.

2. The facial bionic ceramide according to claim 1, characterized in that The facial bionic oil fatty acid also contains 0-0.5% linolenic acid.

3. The facial bionic ceramide according to claim 1, characterized in that The facial bionic fatty acid phytosphingosine ceramides include: eicosapentaenoic acid phytosphingosine ceramide, docosenoic acid phytosphingosine ceramide, oleic acid phytosphingosine ceramide, linoleic acid phytosphingosine ceramide, palmitic acid phytosphingosine ceramide, stearic acid phytosphingosine ceramide, docosadienoic acid phytosphingosine ceramide, and nervonic acid phytosphingosine ceramide; The facial bionic fatty acid sphingosine ceramides include: eicosapentaenoic acid sphingosine ceramide, docosenoic acid sphingosine ceramide, oleic acid sphingosine ceramide, linoleic acid sphingosine ceramide, palmitic acid sphingosine ceramide, stearic acid sphingosine ceramide, docosadienoic acid sphingosine ceramide, and neratic acid sphingosine ceramide.

4. The facial bionic ceramide according to claim 3, characterized in that: The facial biomimetic fatty acid phytosphingosine ceramide also includes linolenic acid phytosphingosine ceramide; the facial biomimetic fatty acid sphingosine ceramide also includes linolenic acid sphingosine ceramide.

5. The facial bionic ceramide according to any one of claims 1 to 4, characterized in that: The facial biomimetic fatty acid phytosphingosine ceramide and / or the facial biomimetic fatty acid sphingosine ceramide include the compound itself, its isomers, its hydrates and / or its solvates.

6. Use of the facial bionic ceramide according to claim 5 in cosmetics, dietary products or health products.

7. The method for synthesizing facial bionic ceramide according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: (1) preheating facial bionic plant oil to 40-65° C. as material A; dissolving a long-chain sphingosine compound in anhydrous ethanol and heating the mixture to 40-65° C. as material B; (2) mixing the material A and the material B through a micro mixer, and then feeding the mixture into a microchannel reactor for continuous flow reaction at a temperature of 70-90° C., collecting the effluent, and performing post-treatment to obtain the facial bionic ceramide.

8. The method for synthesizing facial bionic ceramide according to claim 7, characterized in that: The continuous flow microchannel reactor is a micro-reaction device with a pipeline inner diameter of 0.1 to 2.5 mm and a pipeline volume of 50 to 100 mL.

9. The method for synthesizing facial bionic ceramide according to claim 7, characterized in that: The continuous flow microchannel reactor is a micro-reaction device with a pipeline inner diameter of 0.8 to 2.0 mm and a pipeline volume of 50 to 100 mL.

10. The method for synthesizing facial bionic ceramide according to claim 7, characterized in that: The post-treatment is as follows: cooling the effluent to room temperature, adding an appropriate amount of water, and cooling to 0-6°C to precipitate solids, filtering to obtain a filter cake; rinsing with anhydrous ethanol to obtain a wet product, and then drying under reduced pressure to obtain the facial bionic ceramide.

Images